“Delaying the Onset of Type 1 Diabetes with Teplizumab: A Narrative Review of Autoantibody Screening and Who Would Actually Be Treated”, JCDO, vol. 2, no. 1, pp. 7–12, Oct. 2022, doi: 10.5281/zenodo.22238844.